Drugs Made In America Acquisition (DMAAR) Income Statement (2024 - 2026)
Income Statement report data from Jun 30, 2024 to Mar 31, 2026 for Drugs Made In America Acquisition (DMAAR).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Sep 30, 2024 | Jun 30, 2024 | |
|---|---|---|---|---|---|---|---|
Operating Expenses | |||||||
Selling General And Administrative | 140K (-93.30%) | 2.09M (+703.85%) | 260K (+100.00%) | 130K (-60.61%) | 330K (+135.71%) | 140K (+180.00%) | 50K |
Operating Expenses | 140K (-93.30%) | 2.09M (+703.85%) | 260K (+100.00%) | 130K (-60.61%) | 330K (+135.71%) | 140K (+180.00%) | 50K |
Operating Income | |||||||
Operating Income | -140.00K (-93.30%) | -2.09M (+703.85%) | -260.00K (+100.00%) | -130.00K (-60.61%) | -330.00K (+135.71%) | -140.00K (+180.00%) | -50.00K |
Ebit | -140.00K (-93.30%) | -2.09M (+703.85%) | -260.00K (+100.00%) | -130.00K (-60.61%) | -330.00K (+135.71%) | -140.00K (+180.00%) | -50.00K |
EBITDA | 1.97M (+838.10%) | 210K (-90.37%) | 2.18M (-4.80%) | 2.29M (+83.20%) | 1.25M | -140.00K (+180.00%) | -50.00K |
Other Income / Expenses | |||||||
Interest Income | 2.11M (-8.26%) | 2.30M (-6.12%) | 2.45M (+1.24%) | 2.42M (+52.20%) | 1.59M | - | - |
Net Interest Income | 2.11M (-8.26%) | 2.30M (-6.12%) | 2.45M (+1.24%) | 2.42M (+52.20%) | 1.59M | - | - |
Other Non Operating Income | 2.11M (-75.91%) | 8.76M (+257.55%) | 2.45M (+1.24%) | 2.42M (+52.20%) | 1.59M | - | - |
Net Income | |||||||
Net Income From Continuing Operations | 1.97M (+838.10%) | 210K (-90.37%) | 2.18M (-4.80%) | 2.29M (+83.20%) | 1.25M | -140.00K (+180.00%) | -50.00K |
Net Income | 1.97M (+838.10%) | 210K (-90.37%) | 2.18M (-4.80%) | 2.29M (+83.20%) | 1.25M | -140.00K (+180.00%) | -50.00K |